Kyntra Bio, Inc. (KYNB) stock

KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30

$3.44−0.15 (-4.18%)

Close on Nov 13, 2026Market cap $13.93MP/E 0.1Yield –

Kyntra Bio ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Kyntra Bio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KYNB.

Revenue growth-37.1% · median -0.5%

Operating margin-1089.8% · median -1741.2%

Net margin3967.8% · median -1685.3%

Advertisement
300 × 250

See a number that looks wrong?